Press Releases

April 5, 2017

For more information, contact
Glenn E. Martin at (520) 818-8582

WEED, Inc. USA Goes Global: Forms WEED AUSTRALIA LTD. on the Gold Coast

WEED AUSTRALIA LTD., an Unlisted Public Company, ACN # 617 827 764,
Plans to List on the ASX in Coming Months

TUCSON, AZ / ACCESSWIRE / April 5, 2017 / WEED, Inc. (OTC PINK: BUDZ) (the “Company” or ” WEED”), fka United Mines, Inc., a current information, non-SEC reporting company, announces that it has formed a wholly-owned subsidiary in Australia, namely WEED AUSTRALIA LTD.

Glenn E. Martin, WEED’s CEO, traveled “down under” the month of March 2017 to officially form and open WEED AUSTRALIA LTD. Australia is the first continent to legalize Medicinal Cannabis for strain specific/disease specific, cannabis research. Cannabis and Hemp product development and manufacturing are part of this process.

As a result, WEED plans for its Australian subsidiary to apply for all seven cannabis research, processing and product, import/export and manufacturing licenses available, with variations, along with Cannabis and Hemp import/export in the coming months. Additionally, WEED AUSTRALIA LTD. plans to form The Cannabis Institute of Australia as a non-profit arm that will apply for Cannabis research permits state-by-state in Australia, including both North and South Territories. WEED AUSTRALIA LTD. will work closely with Sangre AgroTech LLC, a U.S.-based entity that has begun a 5-year, $10 million Cannabis Genomic Study for the purpose of completing a global genomic classification of the cannabis plant genus. “The cures are out there, from Autism (ASD) to Epilepsy. I am optimistic about WEED’s global corporate strategy to become a world leader in funding and finding cannabis research discoveries,” stated WEED’s Co-Founder and CEO, Glenn E. Martin.

To assist with this goal, WEED has assembled a unique team of world-respected geneticists, plant biologists, agronomists, engineers, and medical doctors. This team provides decades of expertise and innovation in the fields of genetics, plant biology, plant pathology, phytoecology, and sustainable and environmentally sound agricultural practices.

The WEED Cannabis research teams are focused on the development and application of cannabis-derived compounds for the treatment of human disease. Targeting cannabis-derived molecules which stimulate the endocannabinoid system, the Cannabis research teams in both the USA and Australia will develop the required scientifically-valid/evidence-based cannabis strains for the production of disease-specific cannabis medicines.

The scientific cannabis studies conducted by WEED’s scientific teams should further expand the portfolio of relevant medicinal cannabis strains and their application to the resolution of human disease. Partnering with USA-based Sangre AgroTech LLC, a genomic research and breeding company in the United States, WEED plans to identify, collect, patent, and archive a collection of highly active Medicinal Cannabis strains. Dr. Patrick Williams, Chief Science Officer of Sangre AgroTech LLC, stated, “A comprehensive understanding of the annotated genome of a variety of cannabis strains will provide the blueprints for the development of significant medicinal products for the treatment of human diseases, such as pediatric brain cancer, PTSD, epilepsy, chronic pain, and Crohn’s disease.” Sangre AgroTech LLC is comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available.

“After 47 years of advocacy in this industry, it has been and will continue to be an honor to build out the ‘American Dream’ on a global basis in this new legal cannabis frontier with my co-founders, Nicole Marie Breen, my daughter, and her husband, Ryan Breen,” further states WEED co-founder and CEO, Glenn E. Martin.

Additionally, WEED Inc. announced that it has completed its year end 2016 current information filing and is finishing its PCAOB audit at this time. WEED Inc. plans to return to its former fully reporting status in 2017.

About WEED, Inc.

WEED, Inc. (OTC PINK: BUDZ) is a USA-based public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote the WEED global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family.

WEED does not grow, harvest, produce, or sell any substance in violation of U.S. Federal law under The Federal Controlled Substances Act, and meets all standards of international law in the countries that WEED does business. WEED plans to purchase land and build commercial grade “cultivation & research centers” to consult, assist, manage, and lease to licensed researchers and dispensary owners, along with grow operators on a contract basis, with a concentration on the legal adult use and medical cannabis sector. The Company’s plan is to become a true “Seed-to-Sale” global brand providing infrastructure, financial solutions, medical research, and education, along with real estate solutions in this new emerging market. For additional information about WEED, Inc., please visit

Forward-Looking Statements:

This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Glenn E. Martin
Chairman, President & CEO

Glenn E. Martin
Chairman and Managing Director

For more information, contact:
Glenn E. Martin at (520) 818-8582


Stay Informed

Sign up to receive our latest news and announcements